Lixte Biotechnology Holdings, Inc. (LIXT) NASDAQ
Currency In USD
AD
- General
- Statistics
- Historical Data
- Profile
- Financials
AD
Currency In USD
| Previous Close | 7.67 |
| Open | 7.81 |
| Day High | 7.95 |
| Day Low | 7 |
| 52-Week High | 8.38 |
| 52-Week Low | 2.02 |
| Volume | 615,057 |
| Average Volume | 238,595 |
| Market Cap | 89.11M |
| PE | -6.38 |
| EPS | -1.13 |
| Moving Average 50 Days | 5.83 |
| Moving Average 200 Days | 4.31 |
| Change | -0.46 |
Data not available
LIXTE Biotechnology Appoints Sidney Braun as CEO of its Liora Technologies Europe Ltd. Subsidiary
GlobeNewswire Inc.
Feb 18, 2026 1:00 PM GMT
BOCA RATON, Fla., Feb. 18, 2026 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. (“LIXTE” or the “Company”) (Nasdaq: LIXT), a clinical stage pharmaceutical and med-tech company focused on advancing cancer treatments, today announced it has ap
DE LA SOUL-LED “GOOD HEALTH SUMMIT” LAUNCHES FEBRUARY 19 AT MOREHOUSE COLLEGE
GlobeNewswire Inc.
Jan 21, 2026 1:00 PM GMT
Event Sponsored by LIXTE Biotechnology Holdings,Developer of Breakthrough Cancer Therapies Atlanta, GA, Jan. 21, 2026 (GLOBE NEWSWIRE) -- Inspired by the music, legacy, and lived experiences of De La Soul, the inaugural Good Health: Mind, Body & So
LIXTE Biotechnology Attending the DealFlow Discovery Conference, January 28-29
GlobeNewswire Inc.
Jan 20, 2026 1:00 PM GMT
BOCA RATON, Fla., Jan. 20, 2026 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. (“LIXTE” or the “Company”) (Nasdaq: LIXT), a clinical-stage pharmaceutical company advancing LB-100, a first-in-class inhibitor of protein phosphatase 2A (PP2A),